Loading
Renal Cell Carcinoma Treatment / Multiple and Secondary Primary Cancers / Ferroptosis and Cancer Prognosis · Journal article
Clinical and Experimental Medicine · September 9, 2026
Encouraging direction, but not yet definitive.
A three-gene onco-immune score (RORC, TGFB1, SOCS1) derived from Cox regression in TCGA-KIRC and measured in archival FFPE tissue is independently associated with overall survival in ccRCC across stage, grade, age, and tumor purity. The score marks immunologically exhausted tumors and may support risk stratification, but requires prospective validation before clinical implementation.
Retrospective cohort study with biomarker discovery and external dataset validation. Clear cell renal cell carcinoma patients with archival FFPE tumor tissue available; 88 patients analyzed; derivation performed in TCGA-KIRC cohort. Intervention: Three-gene onco-immune score (RORC, TGFB1, SOCS1) derived and computed from NanoString nCounter quantification of archival FFPE tumor tissue. Compared with: High-risk versus low-risk classification based on score; validation against external datasets. n = 88. Not stated.
Three-gene score associated with worse overall survival independently of stage, grade, age, and tumor purity (HR 1.57, 95% CI 1.28–1.92, p < 0.001) in TCGA-KIRC Association with tumor grade reproduced across external cohorts High-risk tumors characterized by immune exhaustion: interferon and IL-6/JAK/STAT3 upregulation, fibroblast and macrophage enrichment, lower predicted checkpoint-response rate
RORC associated with favorable metabolic module; TGFB1 associated with adverse inflammatory-myeloid module
If prospectively validated, this score could improve risk stratification and identify patients with immune-exhausted tumors who may benefit from combination immunotherapy strategies. The use of archival FFPE tissue makes it potentially accessible for clinical implementation without additional testing.
A retrospective derivation and validation study identifying a three-gene prognostic score in ccRCC with independent association to overall survival; sound design but limited by retrospective nature, single-center derivation cohort, and lack of prospective validation.
As stated by the source record.
Quoted from the source exactly as published.
If prospectively validated, this score could improve risk stratification and identify patients with immune-exhausted tumors who may benefit from combination immunotherapy strategies. The use of archival FFPE tissue makes it potentially accessible for clinical implementation without additional testing.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer. Despite advances in anti-angiogenic and immune checkpoint therapy, accurate prognostic markers that run on archival tissue are still lacking. In this retrospective study, we quantified twelve onco-immune genes in FFPE tumor blocks from 88 ccRCC patients using the NanoString nCounter platform. A three-gene score (RORC, TGFB1, and SOCS1) was derived in TCGA-KIRC by Cox regression and evaluated in external bulk, single-cell, and spatial datasets. The twelve panel genes were profiled in the archival FFPE tumors, and the score was computed for every patient. In TCGA-KIRC, the score was associated with worse overall survival independently of stage, grade, age, and tumor purity (HR 1.57, 95% CI 1.28–1.92, p < 0.001), and its association with tumor grade was reproduced across external cohorts. Further, high-risk tumors were inflamed but immune-exhausted, with interferon and IL-6/JAK/STAT3 up-regulation, fibroblast and macrophage enrichment, and a lower predicted checkpoint-response rate. RORC was associated with a favorable metabolic module and TGFB1 with an adverse inflammatory-myeloid module, and interpretable machine learning supported the same directions. We identified a three-gene onco-immune score from an FFPE-compatible panel that is associated with survival independently of stage, grade, and age, and marks immunologically exhausted tumors. The score could assist risk stratification and support precision medicine in ccRCC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.